Dynavax/$DVAX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Dynavax

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Ticker

$DVAX
Primary listing

Industry

Biotechnology

Employees

405

ISIN

US2681582019

Dynavax Metrics

BasicAdvanced
$1.2B
-
-$0.47
1.26
-

What the Analysts think about Dynavax

Analyst ratings (Buy, Hold, Sell) for Dynavax stock.

Bulls say / Bears say

HEPLISAV-B has achieved a 44% market share in the U.S. adult hepatitis B vaccine market by the end of 2024, positioning Dynavax as a market leader. (TipRanks)
Favorable market dynamics, including Medicare policy changes and the inclusion of hepatitis B vaccination in HEDIS measures, are expected to drive further market share and revenue growth for HEPLISAV-B in 2025. (TipRanks)
Dynavax's shingles vaccine program, Z-1018, is progressing well, with Phase I results showing favorable tolerability, and is advancing to a Phase I/II study, indicating potential for future success. (TipRanks)
The FDA declined Dynavax's request to expand the use of its hepatitis B vaccine due to insufficient data, partly stemming from the destruction of trial documents, affecting half of the trial's participants. (Reuters)
Goldman Sachs downgraded Dynavax's stock rating to 'sell' and reduced the price target to $10.00, indicating concerns about the company's future performance. (Defense World)
Dynavax's debt-to-equity ratio stands notably higher than the industry average at 0.37, indicating a heavier reliance on borrowed funds and raising concerns about financial leverage. (Benzinga)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.

Dynavax Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Dynavax Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $DVAX

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs